1. Kedir AA, Desta A, Fesseha G. Factors affecting survival of HIV positive children taking antiretroviral therapy at Adama Referral Hospital and Medical College, Ethiopia. J AIDS Clin Res. 2014; 5(3):1-6.
2. Cohen MH, French AL, Benning L, Kovacs A, Anastos K, Young M, et al. Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. Am J Med. 2002; 113(2): 91-8.
3. Arnaout RA, Lloyd AL, O'Brien TR, Goedert JJ, Leonard JM, Nowak MA. A simple relationship between viral load and survival time in HIV-1 infection. Proc Natl Acad Sci USA. 1999; 96(20): 11549-53.
4. http: //www.unaids.org/en/media/unaids/ contentassets/documents/factsheet/2014/20140716_FactSheet_en.pdf.
5. Ministery of Health. Report of AIDS Control Program in Iran. Tehran: Ministery of Health and Medical Education; 2013.
6. Antiretroviral Therapy Cohort C. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: Collaborative analysis of 13 HIV cohort studies. Clin Infect Dis. 2010; 50(10): 1387-96.
7. Massavon W, Barlow-Mosha L, Mugenyi L, McFarland W, Gray G, Lundin R, et al. Factors determining survival and retention among HIV-infected children and adolescents in a community home-based care and a facility-based family-centred approach in kampala, Uganda: A Cohort Study. ISRN AIDS. 2014; 2014: 852489.
8. Roshanaei G, Sabouri Ghannad M, Saatchi M, Khazaei S, Mirzaei M. Survival rates of human immunodeficiency virus and tuberculosis co-infected patients. Jundishapur J Microbiol. 2014; 7(6): e10565.
9. Mirzaei M, Poorolajal J, Khazaei S, Saatchi M. Survival rate of AIDS disease and mortality in HIV-infected patients in Hamadan, Iran: A registry-based retrospective cohort study (1997-2011). Int J STD AIDS. 2013; 24(11): 859-66.
10. Sepkowitz KA. AIDS-the first 20 years. N Engl J Med. 2001; 344(23): 1764-72.
11. Badcock-Walters P, Bernett T, Bertozzi S, Bollinger L, DeMaria L, et al. State of the art: AIDS and economics. IAEN. 2002: 49-55.
12. Sharp PM, Hahn BH. Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med. 2011; 1(1): a006841.
13. Kaleebu P, French N, Mahe C, Yirrell D, Watera C, Lyagoba F, et al. Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J Infect Dis. 2002; 185(9): 1244-50.
14. http: //aids.behdasht.gov.ir/2015. [Persian]
15. AIDS CGo. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: A collaborative re-analysis. Lancet. 2000; 355.
16. Altisent C, Montoro JB, Ruiz I, Lorenzo JI. Long-term survivors and progression of human immunodeficiency virus infection. N Engl J Med. 1996; 334(16): 1065-6.
17. Darby SC, Ewart DW, Giangrande PL, Spooner RJ, Rizza CR. Importance of age at infection with HIV-1 for survival and development of AIDS in UK haemophilia population. UK Haemophilia Centre Directors' Organisation. Lancet. 1996; 347(9015): 1573-9.
18. Mariotto AB, Mariotti S, Pezzotti P, Rezza G, Verdecchia A. Estimation of the acquired immunodeficiency syndrome incubation period in intravenous drug users: A comparison with male homosexuals. Am J Epidemiol. 1992; 135(4): 428-37.
19. Porter K, Babiker A, Bhaskaran K, Darbyshire J, Pezzotti P, Porter K, et al. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet. 2003; 362(9392): 1267-74.
20. Touloumi G, Pantazis N, Babiker AG, Walker SA, Katsarou O, Karafoulidou A, et al. Differences in HIV RNA levels before the initiation of antiretroviral therapy among 1864 individuals with known HIV-1 seroconversion dates. Aids. 2004; 18(12): 1697-705.
21. Delobel P, Sandres-Saune K, Cazabat M, Pasquier C, Marchou B, Massip P, et al. R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2005; 38(4): 382-92.
22. Brumme ZL, Brumme CJ, Chui C, Mo T, Wynhoven B, Woods CK, et al. Effects of human leukocyte antigen class I genetic parameters on clinical outcomes and survival after initiation of highly active antiretroviral therapy. J Infect Dis. 2007; 195(11): 1694-704.
23. Carrington M, O'Brien SJ. The influence of HLA genotype on AIDS. Annu Rev Med. 2003; 54: 535-51.
24. Hogan CM, Hammer SM. Host determinants in HIV infection and disease. Part 2: Genetic factors and implications for antiretroviral therapeutics. Ann Intern Med. 2001; 134(10): 978-96.
25. Fawzi WW, Msamanga GI, Spiegelman D, Wei R, Kapiga S, Villamor E, et al. A randomized trial of multivitamin supplements and HIV disease progression and mortality. N Engl J Med. 2004; 351(1): 23-32.
26. Marston B, De Cock KM. Multivitamins, nutrition, and antiretroviral therapy for HIV disease in Africa. N Engl J Med. 2004; 351(1): 78-80.
27. Kaiser JD, Campa AM, Ondercin JP, Leoung GS, Pless RF, Baum MK. Micronutrient supplementation increases CD4 count in HIV-infected individuals on highly active antiretroviral therapy: A prospective, double-blinded, placebo-controlled trial. J Acquir Immune Defic Syndr. 2006; 42(5): 523-8.
28. Slama L, Palella FJ, Abraham AG, Li X, Vigouroux C, Pialoux G, et al. Inaccuracy of haemoglobin A1c among HIV-infected men: Effects of CD4 cell count, antiretroviral therapies and haematological parameters. J Antimicrob Chemother. 2014; 14(8): 69-73.
29. Alavi SM, Ahmadi F, Farhadi M. Correlation between total lymphocyte count, hemoglobin, hematocrit and CD4 count in HIV/AIDS patients. Acta Med Iran. 2009; 47(1): 1-4.
30. Bhaskaran K, Hamouda O, Sannes M, Boufassa F, Johnson AM, Lambert PC, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA. 2008; 300(1): 51-9.
31. Sabine C, Collaboration ATC. AIDS events among individuals initiating HAART: Do some patients experience a greater benefit from HAART than others? Aids. 2005; 19(17): 1995-2000.
32. Baum MK, Rafie C, Lai S, Sales S, Page B, Campa A. Crack-cocaine use accelerates HIV disease progression in a cohort of HIV-positive drug users. J Acquir Immune Defic Syndr. 2009; 50(1): 93-9.
33. Peterson PK, Sharp BM, Gekker G, Portoghese PS, Sannerud K, Balfour HH, Jr. Morphine promotes the growth of HIV-1 in human peripheral blood mononuclear cell cocultures. AIDS. 1990; 4(9): 869-73.
34. Mientjes GH, Miedema F, Van Ameijden EJ, Van den Hoek AA, Schellekens PT, Roos MT, et al. Frequent injecting impairs lymphocyte reactivity in HIV-positive and HIV-negative drug users. AIDS. 1991; 5(1): 35-41.
35. Celentano DD, Galai N, Sethi AK, Shah NG, Strathdee SA, Vlahov D, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS. 2001; 15(13): 1707-15.
36. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD, Jr. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet. 1993; 342(8866): 268-72.
37. Erb P, Battegay M, Zimmerli W, Rickenbach M, Egger M. Effect of antiretroviral therapy on viral load, CD4 cell count, and progression to acquired immunodeficiency syndrome in a community human immunodeficiency virus-infected cohort. Swiss HIV cohort study. Arch Intern Med. 2000; 160(8): 1134-40.
38. Sulkowski MS, Mast EE, Seeff LB, Thomas DL. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis. 2000; 30(1): S77-84.